A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2 Positive Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Mar 2017
At a glance
- Drugs Neratinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 03 Mar 2017 This trial is completed in Portugal. (End date: 25 Nov 2016)
- 19 Dec 2016 This trial has been completed in Spain
- 07 Dec 2016 Results of biomarker analysis published in a Puma Biotechnology media release.